Carol Lim, MD
Psychiatry · Boston, MANPI 1649723347
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (39.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 55.9% of the total. Reporting peaked in 2023 at $2,150 and has fallen 97.1% since, to $63 in 2025. Among psychiatry clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $183.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Zimmer Biomet$157
- Teva Pharmaceuticals USA, Inc.$63
- Alkermes, Inc.$47
- Merck$35
- plus $14 from 1 others
What the payments were for
- Consulting fees$1,38036%
- Travel & lodging$1,51739%
- Food & beverage$93324%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 13 | $2,150 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,380 |
| Zimmer Biomet | 1 | $157 |
| Teva Pharmaceuticals USA, Inc. | 2 | $63 |
| Alkermes, Inc. | 2 | $47 |
| Merck | 1 | $35 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NCB$157
How this compares
$3,845 in reported general payments places this provider in the 90th percentile of 1,431 psychiatry providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 415 | $25,231 |
| Aripiprazole | 45 | $2,208 |
| Modafinil | 21 | $1,877 |
| Divalproex Sodium ErDivalproex Sodium | 23 | $1,399 |
| Varenicline Tartrate | 13 | $1,176 |
| Olanzapine | 62 | $855 |
| Hydroxyzine Hcl | 23 | $855 |
| Quetiapine Fumarate | 28 | $828 |
| Ziprasidone Hcl | 14 | $665 |
| Bupropion XlBupropion Hcl | 23 | $657 |
| Atomoxetine Hcl | 14 | $649 |
| Clorazepate Dipotassium | 11 | $535 |
| Haloperidol Decanoate | 15 | $517 |
| Clonazepam | 56 | $511 |
| Haloperidol | 20 | $506 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Boston
- Ximena Sanchez-SamperBoston$258K
- George PapakostasBoston$170K
- Maurizio FavaBoston$120K
- Andrew NierenbergBoston$94K
- Lee GoldsteinBoston$90K
- Gary SachsBoston$81K
- Dan IosifescuBoston$61K
- Lee CohenBoston$51K
- Michael OstacherBoston$39K
- Cristina MontalvoBoston$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.